Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and
characterized in 1999. It is required for the generation of all monomeric forms of amyloid-β …

Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …

Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …

β-amyloid (Aβ)–dependent neuronal hyperactivity is believed to contribute to the circuit
dysfunction that characterizes the early stages of Alzheimer's disease (AD). Although …

Peptides and proteins have been found to possess an inherent tendency to convert from
their native functional states into intractable amyloid aggregates. This phenomenon is …

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and
represents one of the earliest pathomechanistic alterations throughout the AD continuum …

The incidence of Alzheimer's disease (AD) is growing every day and finding an effective
treatment is becoming more vital. Amyloid-β (Aβ) has been the focus of research for several …